![](/img/cover-not-exists.png)
PDG88 COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY
Silva Miguel, L., Paquete, A.T., Borges, M.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.1101
Date:
November, 2019
File:
PDF, 651 KB
2019